<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951103</url>
  </required_header>
  <id_info>
    <org_study_id>Sobi.Elocta-004</org_study_id>
    <nct_id>NCT03951103</nct_id>
  </id_info>
  <brief_title>rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A</brief_title>
  <official_title>A 5-year Chart Review Study of Patients With Haemophilia A With Inhibitors Treated With rFVIIIFc (Elocta®) for Immune Tolerance Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantar Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 5-year chart review study of patients with haemophilia A with inhibitors treated with
      rFVIIIFc (Elocta®) for immune tolerance induction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 5-year multicenter, international, non- interventional, retrospective and prospective
      medical chart review study. Data will be collected from medical records for patients
      diagnosed with haemophilia A who have been, or who are currently, treated with rFVIIIFc for
      ITI . The study will be descriptive in nature and report on baseline characteristics,
      treatment and outcomes for patients who have been, or who are currently, treated with
      rFVIIIFc for ITI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">November 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 6, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ITI with rFVIIIFc: Main dose</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Main dose will be assessed on the prescribed dose (IU/kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ITI with rFVIIIFc: Main injection frequency</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Main injection frequency will be assessed on the prescribed frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ITI with rFVIIIFc: Duration</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Number of treatment months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ITI with rFVIIIFc: Concomitant by-passing agents</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Product name and main dose will be used to describe any concomitant use of by-passing agents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of ITI with rFVIIIFc: Overall outcome</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>The Investigator will assess overall outcome as: success, partial success, failure, early withdrawal or other.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of ITI with rFVIIIFc: Time to undetectable inhibitor titer</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Treatment time to reach undetectable inhibitor levels (&lt;0.6 BU/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of ITI with rFVIIIFc: Time to normal recovery</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Treatment time to reach normal recovery levels (≥66% of the expected value)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of ITI with rFVIIIFc: Time to success</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Treatment time to reach success (see outcome #5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of ITI with rFVIIIFc: Inhibitor titer levels</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>BU/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of ITI with rFVIIIFc: Half-life</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>FVIII half-life (hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of ITI with rFVIIIFc: Recovery level</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>FVIII recovery level (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of ITI with rFVIIIFc: Bleeds</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Number of bleeds per month during ITI-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term outcome after ITI with rFVIIIFc: Occurrence of relapse</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Occurrence of relapse (Yes/No) will be assessed by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term outcome after ITI with rFVIIIFc: Time to relapse</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Time to occurrence of relapse (see outcome #13)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term outcome after ITI with rFVIIIFc: Treatment regimen</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Treatment regimen will be described as: ITI, prophylaxis or on-demand; and also by product used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term outcome after ITI with rFVIIIFc: Bleeds</measure>
    <time_frame>From 2018 to 2023</time_frame>
    <description>Number of bleeds per month.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <arm_group>
    <arm_group_label>Hemophili A patients</arm_group_label>
    <description>Patients treated with rFVIIIFc for ITI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rFVIIIFc</intervention_name>
    <description>Drug according to prescription</description>
    <arm_group_label>Hemophili A patients</arm_group_label>
    <other_name>Elocta</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All haemophilia A patients who have been, or who are currently treated with rFVIIIFc for
        ITI meeting the inclusion and not meeting the exclusion criteria will be invited to
        participate. Approximately 50 patients from Europe and the Middle East are expected to be
        included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with haemophilia A who have been, or who are currently, treated
             with rFVIIIFc for ITI.

          -  Signed and dated informed consent provided by the patient, or the patient's legally
             acceptable representative for patients under the legal age, before any study-related
             data collection are undertaken. Assent should be obtained from paediatric patients
             according to local regulations.

        Exclusion Criteria:

          -  Current participation in any investigational medicinal product trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Lethagen</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Orphan Biovitrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael O'Malley</last_name>
    <phone>+46 8 697 2000</phone>
    <email>michael.omalley@sobi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars-Erik Nilsson</last_name>
    <phone>+46 8 697 2000</phone>
    <email>lars-erik.nilsson@sobi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Berlin-Friedrichshain</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Berlin-Mitte</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Kuwait City</city>
        <country>Kuwait</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Buraydah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Riyadh</city>
        <zip>12233</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site (a)</name>
      <address>
        <city>Riyadh</city>
        <zip>12713</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site (p)</name>
      <address>
        <city>Riyadh</city>
        <zip>12713</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site (a)</name>
      <address>
        <city>Al Ain</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Research Site (p)</name>
      <address>
        <city>Al Ain</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Kuwait</country>
    <country>Norway</country>
    <country>Saudi Arabia</country>
    <country>Switzerland</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elocta</keyword>
  <keyword>rFVIIIFc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

